EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Hyun Woong Park iD, Jae-Hwan Lee iD, Jin-Ok Jeong iD, Diana A Gorog iD, Udaya S Tantry iD, Byeong-Keuk Kim iD, Hyung Joon Joo iD, Kiyuk Chang, Jin-Yong Hwang iD, Young Bin Song, Sung Gyun Ahn iD, Jung-Won Suh und 11 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.70154 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Hyun Woong Park und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daej…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Drug-Eluting Stents, Clopidogrel, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of CYP2C19 genotype in relation to clinical risk is unclear during clopidogrel treatment following drug‐eluting stent (DES) implantation. This study aimed to evaluate the prognostic significance of CYP2C19 genotypes based on clinical risk stratification in DES‐treated patients. From the nationwide multicenter PTRG‐DES (Platelet function and genoType‐Related long‐term progGosis in DES‐treated patients) consortium, patients were classified according to the presence of CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P 2 A 2 RC and TRS 2°P scores. The primary endpoint (1°EP) was a composite of cardiac death, myocardial infarction, and stent thrombosis during a 3‐year follow‐up. Among clopidogrel‐treated patients with CYP2C19 genotyping ( n = 8,163), IMs/PMs (62.1%) demonstrated an increased risk of 1°EP compared with RMs/NMs (hazard ratio [HR]: 1.48; 95% confidence interval [CI]: 1.05–2.07; Log‐rank P < 0.001), Most notable in those with high CHADS‐P2A2RC (≥ 4) and TRS 2°P (≥ 3) scores (HR adj : 1.68; 95% CI: 1.01–2.80; P = 0.047 and HR adj : 1.63; 95% CI: 1.05–2.54; P = 0.029, respectively). In patients with low scores, there was no difference in 1°EP between IMs/PMs vs. RMs/NMs; however, an interaction was observed between acute and chronic coronary syndromes for both low CHADS‐P 2 A 2 RC (HR adj : 2.12; 95% CI: 1.11–4.03 and HR adj : 0.68; 95% CI: 0.34–1.36; P interaction = 0.017) and TRS 2°P scores (HR adj : 2.34; 95% CI: 1.07–5.12 and HR adj : 0.52; 95% CI: 0.22–1.17; P interaction = 0.008). Among clopidogrel‐treated patients, the carriage of the CYP2C19 LoF allele was associated with higher ischemic risk, particularly in those with high clinical risk or an acute coronary syndrome presentation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Drug-Eluting StentsClopidogrelPlatelet Aggregation InhibitorsPercutaneous Coronary InterventionHumansFemaleMaleMiddle AgedAgedRisk AssessmentGenotypePrognosisRisk FactorsThrombosisMyocardial Infarction

Substanzen

Cytochrome P-450 CYP2C19ClopidogrelCYP2C19 protein, humanPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, South Korea.
  • School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, London, UK.
  • Imperial College, National Heart & Lung Institute, London, UK.
  • Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, USA.
  • Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.

ORCID-Profile: Hyun Woong Park, Jae-Hwan Lee, Jin-Ok Jeong, Diana A Gorog, Udaya S Tantry, Byeong-Keuk Kim, Hyung Joon Joo, Jin-Yong Hwang, Sung Gyun Ahn, Woong Gil Choi, Jeehoon Kang, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Young-Hoon Jeong

Zitieren

APA

Park, H. W., Lee, J. H., Jeong, J. O., Gorog, D. A., Tantry, U. S., Kim, B. K., Joo, H. J., Chang, K., Hwang, J. Y., Song, Y. B., Ahn, S. G., Suh, J. W., Choi, W. G., Cho, J. R., Kang, J., Lee, S. Y., Kim, H. S., Kim, M. H., Lim, D. S., …, & PTRG‐DES Consortium Investigators (2025). Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70154

Vancouver

Park HW, Lee JH, Jeong JO, Gorog DA, Tantry US, Kim BK, et al. Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70154

BibTeX
@article{Park2025,
  author = {Park, Hyun Woong and Lee, Jae-Hwan and Jeong, Jin-Ok and Gorog, Diana A and Tantry, Udaya S and Kim, Byeong-Keuk and Joo, Hyung Joon and Chang, Kiyuk and Hwang, Jin-Yong and Song, Young Bin and Ahn, Sung Gyun and Suh, Jung-Won and Choi, Woong Gil and Cho, Jung Rae and Kang, Jeehoon and Lee, Sang Yeub and Kim, Hyo-Soo and Kim, Moo Hyun and Lim, Do-Sun and Shin, Eun-Seok and Gurbel, Paul A and Jeong, Young-Hoon and PTRG‐DES Consortium Investigators, PTRG‐DES Consortium Investigators},
  title = {Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.70154}
}
Kostenlos starten →